Overexpression of fatty acid synthase (FAS)4 is common in aggressive human cancers, and blocking FAS inhibits growth and leads to apoptosis in these cancer cells (1, 2). Although it is now well accepted that increased activity of this enzyme plays a key role in maintaining the metabolic stability of cancer cells, the molecular consequences of inhibiting FAS are still not well understood.One central molecular network commonly altered in cancer pathogenesis and also affected by cancer treatment is that regulated by the transcription factor NF-B. NF-B signaling is constitutively activated in many epithelial solid tumors and hematologic malignancies (3-5), and this activation appears to generally confer resistance to apoptosis as well as enhance growth properties of cancer cells. Consequently, numerous inhibitors of NF-B are being investigated for potential use in treating cancer (6, 7), and bortezomib, a proteosome inhibitor widely used for treating myeloma, is thought to act largely through inhibition NF-B by stabilization of the IB␣ subunit (8, 9). Interestingly, NF-B activity is also inhibited by a number of naturally occurring lipid compounds that have recognized anti-neoplastic properties, including curcumin, resveratol, and coix seed extract (10 -12), providing additional evidence to suggest that NF-B activity supports or promotes the malignant phenotype.NF-B activity does not uniformly contribute to malignancy, however, and in some situations, increased NF-B activity may actually suppress malignant characteristics of cells (13). For example, it has been shown that induction of p53 leads to activation of NF-B, correlating with the ability of p53 to induce apoptosis (14). Thus, at least in some cellular settings, inhibition or loss of NF-B activity abrogates p53-induced apoptosis, indicating that NF-B can be functional in p53-mediated cell death.The role of NF-B signaling in the response of cancer cells to chemotherapy also appears to depend on variables of the particular situation. In many circumstances, activation of NF-B by therapeutic agents appears to inhibit apoptosis and thus attenuates the response to these agents (15-17). However, activation of NF-B by cancer therapeutic agents appears to mediate cell death in other circumstances, including treatment with UV light (18), doxorubicin (19), and paclitaxel (20). In light of the general importance of NF-B to cellular physiology and response to stress and the expectation that manipulations of lipid metabolic pathways could affect NF-B signaling, we investigated the effects of inhibiting FAS on NF-B and the role of NF-B signaling in the response of lung cancer cells to this inhibition. 4 The abbreviations used are: FAS, fatty acid synthase; mIB␣, mutant IB␣; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PGE2, prostaglandin E2; PMA, phorbol 12-myristate 13-acetate; CE, cloning efficiency.
EXPERIMENTAL PROCEDURES